Tag:
meningitis B
Latest Headlines
Latest Headlines
U.K. rejects petition demanding meningitis B vaccine for all children
The U.K. rolled out its meningitis B vaccination program for babies in September, but a petition demanding that it be expanded for all children quickly gathered steam. The Department of Health rejected the petition on Wednesday, saying that offering the jab to all children would not be cost-effective.
Pfizer touts Trumenba immunogenicity when administered with Menactra, Adacel
In a potential boost to uptake and adherence, Pfizer reported promising data this week on its meningitis B vaccine Trumenba administered along with Menactra and Adacel from Sanofi Pasteur.
With limited ACIP nod, U.S. universities take different approaches to Pfizer, GSK MenB jabs
The CDC's Advisory Committee on Immunization Practices has stopped short of recommending routine meningitis B immunization, leaving the decision to doctors and families whether young adults aged 16 to 23 should be vaccinated. Result? U.S. universities are taking varying approaches when it comes to MenB jabs and their students.
ACIP gives Glaxo, Pfizer a lukewarm decision for new meningitis B vaccines
The CDC's Advisory Committee on Immunization Practices (ACIP) voted on Wednesday to expand its recommendation for meningitis B vaccines, but it wasn't the broad recommendation that many were hoping to see.
Pfizer, Novartis get MenB ACIP nod--but not the one they're really after
Pfizer and Novartis officially have a nod from the CDC's Advisory Committee on Immunization Practices (ACIP) for their recently approved meningitis B vaccines. Problem is, it doesn't cover nearly as large a population as the pharma giants would like.
Novartis' Bexsero picks up FDA nod--but with competition looming, approval isn't everything
After years of pinning its vaccine ambitions on meningitis B shot Bexsero, Novartis' FDA approval is here. But as it prepares to fork over the jab--along with the bulk of its vaccines business--to deal partner GlaxoSmithKline, there are other hurdles in the way of its success--including some new competition from Pfizer.
U.K. health secretary: Novartis holding government to 'ransom' with Bexsero pricing
Earlier this month, U.K. politicians asked Prime Minister David Cameron to explain why Novartis' Bexsero, approved as an addition to the country's childhood immunization schedule 8 months back, had yet to be covered by the National Health Service. Now, Cameron has asked Health Secretary Jeremy Hunt to do the same--and Hunt is pointing the finger at the Swiss pharma.
U.K. pols press PM Cameron on Bexsero coverage delay
Ongoing price negotiations between the U.K. government and Novartis have so far kept the meningitis B vaccine Bexsero out of the public's reach, and now members of Parliament are asking where it is.
Pfizer beats out Novartis with FDA MenB nod
We have a winner. In a two-horse race to grab the first-ever U.S. approval for a meningitis B vaccine, Pfizer has emerged victorious, nabbing the FDA's blessing Wednesday.
Bexsero could be cost-effective for England, model says--but not at Novartis' price
What's the value of Novartis' meningitis B vaccine, Bexsero, to the U.K.? It's a question the company and the country's government have been debating for months now, unable to come to terms on a reasonable price for the jab. But medical journal The BMJ might have an answer.
